MediWound Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Core Insights - MediWound Ltd. reported a revenue of $5.7 million for Q2 2025, reflecting a 43% increase from the previous quarter [5][12] - The company is actively enrolling patients in the VALUE Phase III trial for EscharEx, targeting 216 patients across 40 sites in the U.S. and Europe [6][2] - NexoBrid is gaining commercial traction in the U.S., with a reported 52% year-over-year revenue growth [6][2] Clinical Developments - The VALUE Phase III trial for EscharEx is ongoing, with an interim sample size assessment planned for mid-2026 [6] - New collaborations with Essity and Convatec have been established to support EscharEx trials, enhancing the company's clinical partnerships [6][2] - The trial now includes JOBST for compression therapy and will incorporate AQUACEL for wound dressing in the planned DFU trial [6] Financial Performance - Revenue for the first half of 2025 was $9.7 million, compared to $10.0 million in the same period of 2024 [12] - Gross profit for Q2 2025 was $1.3 million, representing 23.5% of total revenue, an improvement from 8.8% in the prior-year period [12] - Research and development expenses increased to $3.5 million in Q2 2025, driven by investments in the EscharEx VALUE Phase III trial [12] Manufacturing and Expansion - The commissioning of MediWound's expanded manufacturing facility is on track, with full operational readiness expected by year-end 2025 [6][2] - The facility is designed to increase NexoBrid production capacity six-fold to meet anticipated demand [6] Funding and Financial Position - The company received an additional $3.6 million in funding from the U.S. Department of Defense to advance NexoBrid's development [6] - As of June 30, 2025, MediWound had cash and cash equivalents of $32.9 million, down from $43.6 million at the end of 2024 [8]